279 results
10-Q
2022 Q3
PRPO
Precipio Inc
10 Nov 22
Quarterly report
4:02pm
access or fax) for the patient’s laboratory report, per the contract.
Clinical research grants
Control of the clinical research services … for our securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may harm our
10-Q
2022 Q2
PRPO
Precipio Inc
11 Aug 22
Quarterly report
4:02pm
in time based on the delivery method (web-portal access or fax) for the patient’s laboratory report, per the contract.
Clinical research grants
Control … securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may harm our
8-K
EX-99.1
PRPO
Precipio Inc
20 Jul 22
Agreement Enhances Precipio’s Product Reach to US Laboratories
7:16pm
access to laboratories across the United States for Precipio’s HemeScreen suite of products. This partnership is a logical expansion of Precipio’s … with the Fisher Healthcare channel will expand access to customers and drive distribution and revenue for our HemeScreen product suite”, said Keith Meadors
8-K
EX-99.1
PRPO
Precipio Inc
13 Jun 22
Regulation FD Disclosure
5:09pm
existing channel distributors HemeScreen Segments: Benefits: Rapid direct access to target market Reduces time to market Avoids costly sales team IV
10-Q
2022 Q1
PRPO
Precipio Inc
11 May 22
Quarterly report
4:01pm
recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient’s laboratory
DEF 14A
bgx82
28 Apr 22
Definitive proxy
4:54pm
10-K
s7ier
30 Mar 22
Annual report
5:04pm
8-K
EX-99.1
edgvfa45bh4vo7icc
25 Feb 22
Precipio Releases Year-End 2021 Preliminary Unaudited Results and Outlook for 2022
6:51pm
10-Q
lem uoaqgmhw
12 Nov 21
Quarterly report
4:02pm
10-Q
nc65sdwiloq7wvjc
12 Aug 21
Quarterly report
4:07pm
10-Q
5wngb6
14 May 21
Quarterly report
4:01pm
DEF 14A
hi22ehc74y0fvso
29 Apr 21
Definitive proxy
4:31pm
8-K
EX-1.01
jb5zul0v raukjx2n1
2 Apr 21
Entry into a Material Definitive Agreement
3:00pm
424B5
ucwx9h
2 Apr 21
Prospectus supplement for primary offering
2:00pm
10-K
na61exots qyeag
29 Mar 21
Annual report
4:29pm
10-Q
d8rnwdb yf
13 Nov 20
Quarterly report
4:01pm
10-Q
004d0hu
13 Aug 20
Quarterly report
3:07pm
424B3
9yxua42jstv
7 Jul 20
Prospectus supplement
5:27pm
S-1
i1q0i vq5ewk7icazseb
26 Jun 20
IPO registration
5:18pm
10-Q
fvl0t
14 May 20
Quarterly report
4:05pm